Concepedia

James R. Hitchin

JR

15

Publications

1.4K

Citations

14

H-Index

2011

Active since

Affiliations

Cancer Research UK Manchester Institute(Current)

University of Manchester

Pfizer (United Kingdom)

AstraZeneca (United Kingdom)

Leuka

James R. Hitchin is an author at Cancer Research UK Manchester Institute specializing in medicine, drug discovery, and natural sciences.

ORCID

Top concepts

Publications per year

2011–2022

15

Publications

15

The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells

William J. Harris, Xu Huang, James T. Lynch et al. · Cancer Cell · 2012 · 551 citations

, , +11

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia

Alba Maiqués-Díaz, Gary J. Spencer, James T. Lynch et al. · Cell Reports · 2018 · 218 citations · Full text

First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib

Dominic I. James, Kate M. Smith, Allan M. Jordan et al. · ACS Chemical Biology · 2016 · 137 citations · Full text

, , +13

Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments

James R. Hitchin, Julian Blagg, Rosemary Burke et al. · MedChemComm · 2013 · 63 citations

, , +20

Novel Steroid Inhibitors of Glucose 6-Phosphate Dehydrogenase

Niall M. Hamilton, Martin D. Dawson, Emma Fairweather et al. · Journal of Medicinal Chemistry · 2012 · 62 citations · Full text

, , +15

Rows per page

1–5 of 15